phosphoribosyl-N-formylglycineamide
Also Known As:
formylglycinamide ribonucleotide; formylglycineamideribotide
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Aguilar, Joanna M H:
1 article
(01/2021)
|
| 2. | Alt, Jesse:
1 article
(01/2021)
|
| 3. | Dash, Ranjeet P:
1 article
(01/2021)
|
| 4. | Gori, Sadakatali S:
1 article
(01/2021)
|
| 5. | Lemberg, Kathryn M:
1 article
(01/2021)
|
| 6. | Majer, Pavel:
1 article
(01/2021)
|
| 7. | Pal, Arindom:
1 article
(01/2021)
|
| 8. | Rais, Rana:
1 article
(01/2021)
|
| 9. | Slusher, Barbara S:
1 article
(01/2021)
|
| 10. | Sun, Qi:
1 article
(01/2021)
|
Related Diseases
| 1. | Neoplasms (Cancer)
|
| 2. | Hepatocellular Carcinoma (Hepatoma)
06/01/1984
- " The liver and hepatoma 3924A FGAM synthetases were saturated at formylglycinamide ribonucleotide, adenosine triphosphate, and L-glutamine concentrations of 0.1, 7.0, and 0.5 mM, respectively; both enzymes had a pH optimum of 7.4. " 06/01/1984
- " In the crude extracts of normal rat liver and hepatoma 3924A, the apparent KmS of FGAM synthetase for formylglycinamide ribonucleotide, adenosine triphosphate and L-glutamine were 0.06, 1.5, and 0.03 mM, respectively. "
|
|
Related Drugs and Biologics